These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 20147531)
1. CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. Liu Y; Bando Y; Vargas-Lowy D; Elyaman W; Khoury SJ; Huang T; Reif K; Chitnis T J Neurosci; 2010 Feb; 30(6):2025-38. PubMed ID: 20147531 [TBL] [Abstract][Full Text] [Related]
2. Mannan-MOG35-55 Reverses Experimental Autoimmune Encephalomyelitis, Inducing a Peripheral Type 2 Myeloid Response, Reducing CNS Inflammation, and Preserving Axons in Spinal Cord Lesions. Dagkonaki A; Avloniti M; Evangelidou M; Papazian I; Kanistras I; Tseveleki V; Lampros F; Tselios T; Jensen LT; Möbius W; Ruhwedel T; Androutsou ME; Matsoukas J; Anagnostouli M; Lassmann H; Probert L Front Immunol; 2020; 11():575451. PubMed ID: 33329540 [TBL] [Abstract][Full Text] [Related]
3. High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. Oxombre B; Lee-Chang C; Duhamel A; Toussaint M; Giroux M; Donnier-Maréchal M; Carato P; Lefranc D; Zéphir H; Prin L; Melnyk P; Vermersch P Br J Pharmacol; 2015 Apr; 172(7):1769-82. PubMed ID: 25521311 [TBL] [Abstract][Full Text] [Related]
4. An Oriental Medicine, Hyungbangpaedok-San Attenuates Motor Paralysis in an Experimental Model of Multiple Sclerosis by Regulating the T Cell Response. Choi JH; Lee MJ; Jang M; Kim EJ; Shim I; Kim HJ; Lee S; Lee SW; Kim YO; Cho IH PLoS One; 2015; 10(10):e0138592. PubMed ID: 26444423 [TBL] [Abstract][Full Text] [Related]
5. Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway. Li G; Yamasaki R; Fang M; Masaki K; Ochi H; Matsushita T; Kira JI Sci Rep; 2018 Jan; 8(1):1933. PubMed ID: 29386552 [TBL] [Abstract][Full Text] [Related]
6. Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation. Becquet L; Abad C; Leclercq M; Miel C; Jean L; Riou G; Couvineau A; Boyer O; Tan YV J Neuroinflammation; 2019 Mar; 16(1):64. PubMed ID: 30894198 [TBL] [Abstract][Full Text] [Related]
7. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Kozela E; Lev N; Kaushansky N; Eilam R; Rimmerman N; Levy R; Ben-Nun A; Juknat A; Vogel Z Br J Pharmacol; 2011 Aug; 163(7):1507-19. PubMed ID: 21449980 [TBL] [Abstract][Full Text] [Related]
8. Tropisetron diminishes demyelination and disease severity in an animal model of multiple sclerosis. Aminian A; Noorbakhsh F; Ghazi-Khansari M; Kafami L; Javadi S; Hassanzadeh G; Rahimian R; Dehpour AR; Mehr SE Neuroscience; 2013 Sep; 248():299-306. PubMed ID: 23774631 [TBL] [Abstract][Full Text] [Related]
9. Direct angiotensin type 2 receptor (AT2R) stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice. Valero-Esquitino V; Lucht K; Namsolleck P; Monnet-Tschudi F; Stubbe T; Lucht F; Liu M; Ebner F; Brandt C; Danyel LA; Villela DC; Paulis L; Thoene-Reineke C; Dahlöf B; Hallberg A; Unger T; Sumners C; Steckelings UM Clin Sci (Lond); 2015 Jan; 128(2):95-109. PubMed ID: 25052203 [TBL] [Abstract][Full Text] [Related]
10. A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS. Sinha S; Subramanian S; Proctor TM; Kaler LJ; Grafe M; Dahan R; Huan J; Vandenbark AA; Burrows GG; Offner H J Neurosci; 2007 Nov; 27(46):12531-9. PubMed ID: 18003831 [TBL] [Abstract][Full Text] [Related]
11. Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNS. Lee JH; Halperin-Sheinfeld M; Baatar D; Mughal MR; Tae HJ; Kim JW; Carter A; Lustig A; Snir O; Lavie G; Okun E; Mattson MP; Sredni B; Taub DD Neuromolecular Med; 2014 Jun; 16(2):292-307. PubMed ID: 24272426 [TBL] [Abstract][Full Text] [Related]
12. Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis. O'Sullivan D; Green L; Stone S; Zareie P; Kharkrang M; Fong D; Connor B; La Flamme AC PLoS One; 2014; 9(8):e104430. PubMed ID: 25116424 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-33 deficiency exacerbated experimental autoimmune encephalomyelitis with an influence on immune cells and glia cells. Xiao Y; Lai L; Chen H; Shi J; Zeng F; Li J; Feng H; Mao J; Zhang F; Wu N; Xu Y; Tan Z; Gong F; Zheng F Mol Immunol; 2018 Sep; 101():550-563. PubMed ID: 30173119 [TBL] [Abstract][Full Text] [Related]
14. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation. Ingwersen J; Wingerath B; Graf J; Lepka K; Hofrichter M; Schröter F; Wedekind F; Bauer A; Schrader J; Hartung HP; Prozorovski T; Aktas O J Neuroinflammation; 2016 Feb; 13():48. PubMed ID: 26920550 [TBL] [Abstract][Full Text] [Related]
15. Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways. Al-Ghezi ZZ; Miranda K; Nagarkatti M; Nagarkatti PS Front Immunol; 2019; 10():1921. PubMed ID: 31497013 [TBL] [Abstract][Full Text] [Related]
16. Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis. Breakell T; Tacke S; Schropp V; Zetterberg H; Blennow K; Urich E; Kuerten S Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962135 [TBL] [Abstract][Full Text] [Related]
17. Korean Red Ginseng and Ginsenoside-Rb1/-Rg1 Alleviate Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells and Upregulating Regulatory T Cells. Lee MJ; Jang M; Choi J; Chang BS; Kim DY; Kim SH; Kwak YS; Oh S; Lee JH; Chang BJ; Nah SY; Cho IH Mol Neurobiol; 2016 Apr; 53(3):1977-2002. PubMed ID: 25846819 [TBL] [Abstract][Full Text] [Related]
18. Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis. van Loo G; Sze M; Bougarne N; Praet J; Mc Guire C; Ullrich A; Haegeman G; Prinz M; Beyaert R; De Bosscher K Mol Endocrinol; 2010 Feb; 24(2):310-22. PubMed ID: 19965930 [TBL] [Abstract][Full Text] [Related]
19. Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells. Kato H; Ito A; Kawanokuchi J; Jin S; Mizuno T; Ojika K; Ueda R; Suzumura A Mult Scler; 2004 Dec; 10(6):651-9. PubMed ID: 15584490 [TBL] [Abstract][Full Text] [Related]
20. Paricalcitol improves experimental autoimmune encephalomyelitis (EAE) by suppressing inflammation via NF-κB signaling. Zhang D; Qiao L; Fu T Biomed Pharmacother; 2020 May; 125():109528. PubMed ID: 32106388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]